Novel approaches to tuberculosis vaccine development

Stefan H E Kaufmann; January Weiner; C Fordham von Reyn

doi:10.1016/j.ijid.2016.10.018

Novel approaches to tuberculosis vaccine development

Int J Infect Dis. 2017 Mar:56:263-267. doi: 10.1016/j.ijid.2016.10.018. Epub 2016 Nov 2.

Authors

Stefan H E Kaufmann¹, January Weiner², C Fordham von Reyn³

Affiliations

¹ Max Planck Institute for Infection Biology, Department of Immunology, Charitéplatz 1, 10117 Berlin, Germany. Electronic address: Kaufmann@mpiib-berlin.mpg.de.
² Max Planck Institute for Infection Biology, Department of Immunology, Charitéplatz 1, 10117 Berlin, Germany.
³ Infectious Disease and International Health, Geisel School of Medicine, Hanover, New Hampshire, USA.

PMID: 27816661
DOI: 10.1016/j.ijid.2016.10.018

Abstract

Tuberculosis (TB) remains the deadliest infectious disease. The widely used bacille Calmette-Guérin (BCG) vaccine offers only limited protection against TB. New vaccine candidates for TB include subunit vaccines and inactivated whole-cell vaccines, as well as live mycobacterial vaccines. Current developments in TB vaccines are summarized in this review.

Keywords: Post-exposure vaccine; Pre-exposure vaccine; Preventive vaccine; Subunit vaccine; Therapeutic vaccine; Whole-cell vaccine.

Publication types

Review

MeSH terms

Animals
Humans
Mycobacterium tuberculosis / immunology
Tuberculosis / prevention & control
Tuberculosis Vaccines*
Vaccines, Attenuated / immunology

Substances

Tuberculosis Vaccines
Vaccines, Attenuated